|
|
|
Volumn 26, Issue 7, 2011, Pages 1-5
|
|
Special report: companion diagnostics--example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
B RAF KINASE;
ARTICLE;
BIOMEDICAL TECHNOLOGY ASSESSMENT;
BLUE CROSS BLUE SHIELD;
CLINICAL TRIAL (TOPIC);
DIAGNOSTIC PROCEDURE;
DIAGNOSTIC TEST APPROVAL;
DRUG ANTAGONISM;
FOOD AND DRUG ADMINISTRATION;
GENETICS;
HUMAN;
MELANOMA;
METHODOLOGY;
MOLECULAR DIAGNOSIS;
MOLECULARLY TARGETED THERAPY;
MUTATION;
PATIENT SELECTION;
PERSONALIZED MEDICINE;
PHARMACOGENETICS;
UNITED STATES;
BLUE CROSS BLUE SHIELD INSURANCE PLANS;
CLINICAL TRIALS AS TOPIC;
DIAGNOSTIC TECHNIQUES AND PROCEDURES;
DIAGNOSTIC TEST APPROVAL;
HUMANS;
INDIVIDUALIZED MEDICINE;
MELANOMA;
MOLECULAR DIAGNOSTIC TECHNIQUES;
MOLECULAR TARGETED THERAPY;
MUTATION;
PATIENT SELECTION;
PHARMACOGENETICS;
PROTO-ONCOGENE PROTEINS B-RAF;
TECHNOLOGY ASSESSMENT, BIOMEDICAL;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84873036366
PISSN: None
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|